Dr.Shital Jadhav (Pg Scholar) (Kaumarbhritya)

 Guided By :- Dr. Sudha Singh (M.D Kaumarbhritya),

Dr. Madhavi S Deodas (Guide & H.O.D Department of Kaumarbhritya, College of Ayurved Akurdi-Pune) 

Abstract :

Guillain-Barre syndrome (GBS) is an acute, rapidly evolving areflexic motor paralysis with or without sensory disturbance. It occurs year around at a rate of between 1 and 4 cases per 100,000 annually. Increasing data indicate that it is an autoimmune disease, often triggered by a preceding viral or bacterial infection with organisms such as Campylobacter jejuni, Helicobacter pylori, or Mycoplasma pneumoniae. Vaccination against the flu, rabies, and meningitis are also documented precipitating factors that have been reported. Investigations include Electromyography, CSF studies and serum CK levels. To date, treatment for GBS has been aimed primarily at immunomodulation (IVIG). Mamsa-Medogata Vata is the condition that can be categorized under GBS due to proximity of their clinical presentation.

REFERENCES

   1.      Longo DL, Fauci AS, Kasper DL, Jameson JL, Hauser SL, Loscalzo J. Vol. 2. New York, NY: McGraw Hill; 2010. Harrison's Principle of Internal Medicine; p. 3473.

2.      Harve B Sarnat,  Vol. 2, 2008, Nelson textbook of pediatrics, 18 th edition; p 2565

3.      Lee JH, Sung IY, Rew IS. Clinical presentation and prognosis of childhood Guillain-Barré syndrome. J Paediatr Child Health. 2008 Jul-Aug. 44(7-8):449-54. [Medline].

4.      Tripathi R. Charak Samhita of Charaka, Chikitsasthan, Vatvyadhi Chikitsa. Varanasi: Chaukhamba Sanskrit Series; 2009. p. 693.

5.      Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005). J Clin Neuromuscul Dis. 2009 Sep. 11(1):1-6.

6.      Tripathi R. Charak Samhita of Charaka, Chikitsasthan, Vatvyadhi Chikitsa. Varanasi: Chaukhamba Sanskrit Series; 2009. p. 701.

7.      Tripathi R. Charak Samhita of Charaka, Chikitsasthan, Vatvyadhi Chikitsa. Varanasi: Chaukhamba Sanskrit Series; 2009. p. 693.

8.      Mishra SN. Bhaishajya Ratnavali of Govindadas Sen, Jwaraadhikar. Varanasi: Chaukhamba Sanskrit Series; 2007. p. 218..

9.      Amlapitta Chikitsa Shlok 1-5. Varanasi: Chaukhamba Sanskrit Series; 2010. Bhisagratna and Brahmasankar Sastri Yogratnakar; p. 244.

10.  Shastri A. Chapter 4, Verse 16. Varanasi: Dalhan Commentary Chaukhamba Sanskrit Series; 2007. Sushrut Samhita of Sushruta Sharir Sthan, Garbhavyakaran; p. 59.

11.  Singh SS, Pandey SC, Srivastav S. Chemical and medicinal properties of tinospora cordifolia. Indian J Pharmacol. 2003;35:83–91.

12.  Krishna KL, Bhatt J, Patel J. Guduchi (Tinospora cordifolia): Biological and medicinal properties, a review. Internet J Altern Med. 2009;6:10–5.

13.  Mishra SN. Bhaishajya Ratnavali of Govindadas Sen Vatvyadhirogaadhikar. Varanasi: Chaukhamba Sanskrit series; 2007. p. 530.

14.  Joshi YG. Charak Samhita of Charaka, Vimansthan Rogbhishakjitiyaviman. Chapter 8, Verse 97-98. Pune: Vaidya Mitra Publications; 2003. p. 599.

15.  Longo DL, Fauci AS, Kasper DL, Jameson JL, Hauser SL, Loscalzo J. Entitled “GBS”. Part 17, Chapter 385. II. New York, NY: McGraw Hill; Harrison's Principle of Internal Medicine; p. 3477.